PRJNA860231
Pharmacologic activation of angiotensin-converting enzyme II alleviates diabetic cardiomyopathy in db/db mice by reducing reactive oxidative stress
In the present study, we aimed to evaluate the hypothesis that the enhancement of ACE2, using a US Food and Drug Administration (FDA)-approved ACE2 activator (diaminazene aceturate, DIZE), would have cardioprotective roles in a murine DCM.